Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: A systematic review and meta-analysis

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1427-1434

  Park, H S ^a,b,c   Schoenfeld, J D ^a,d   Mailhot, R B ^a,e   Shive, M ^a,f   Hartman, R I ^a,g   Ogembo, R ^a,h   Mucci, L A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Meta analysis; Prostate cancer; Radical prostatectomy; Radiotherapy; Recurrence; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; EMBASE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDLINE; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

EID: 84878428458     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt077     Document Type: Article

References (61)

1. Graaf MR, Richel DJ, van Noorden CJ et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30(7): 609-641.
2. Hamilton RJ, Freedland SJ. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 2008; 18(3): 333-339.
3. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9(1): 10-19.
4. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367(19): 1792-1802.
5. Mann D, Reynolds K, Smith D et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008; 42(9): 1208-12015.
6. Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162(4): 318-325.
7. Flick ED, Habel LA, Chan KA et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2218-2225.
8. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98(24): 1819-1825.
9. Jacobs EJ, Rodriguez C, Bain EB et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2213-2217.
10. Kollmeier MA, Katz MS, Mak K et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79(3): 713-718.
11. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123(4): 899-904.
12. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120(4): 833-843.
13. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk: a meta-analysis. J Am Med Assoc 2006; 295(1): 74-80.
14. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007; 62(8): 879-887.
15. Stein EA, Corsini A, Gimpelewicz CR et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 2006; 60(9): 1028-1034.
16. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case- control studies. Eur J Cancer Prev 2008; 17(3): 259-268.
17. Murtola TJ, Tammela TL, Lahtela J et al. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2226-2232.
18. Bonkhoff H. Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer 2012; 2012: 593241.
19. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11): 4447-4454.
20. Wilt TJ, MacDonald R, Rutks I et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148(6): 435-448.
21. Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 2003; 62(Suppl 1): 46-54.
22. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61(5): 1285-1290.
23. Moyad MA, Merrick GS, Butler WM et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005; 66 (6):1150-1154.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188.
25. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
26. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8: 101-129.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558.
28. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in metaanalyses. BMJ 2003; 327(7414): 557-560.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4): 1088-1101.
30. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
31. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283(15): 2008-2012.
32. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
33. Marcella SW, David A, Ohman-Strickland PA et al. Statin use and fatal prostate cancer: a matched case-control study. Cancer 2012; 118(16): 4046-52.
34. Niraula S, Pond G, De Wit R et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2011; 1-8.
35. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence following radical prostatectomy: results from the search database. J Urol 2009; 181(4): 574.
36. Ritch C, Hruby G, Badani K et al. Statin drugs, prostate specific antigen and biochemical outcome following radical prostatectomy. J Urol 2010; 183(4): e720-e721.
37. Hamilton R, Vijai J, Gallagher D et al. Analysis of statin medication, genetic variation and prostate cancer outcomes. J Urol 2011; 185(4): e401.
38. Shippy AM, Katz MS, Yamada Y et al. Statin use and clinical outcomes: after high dose radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 69(3): S113.
39. Katz MS, Carroll PR, Cowan JE et al. Association of statin and nonsteroidal antiinflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010; 106(5): 627-632.
40. Lavery H, Hobbs A, Ghanaat M et al. Preoperative statin use associated with lower PSA but similar histopathologic outcomes. J Urol 2011; 185(4): e61.
41. Sharma NK, Ruth K, Horwitz E et al. Statin use prior to radiation therapy for prostate cancer does not improve outcome: the Fox Chase experience. Int J Radiat Oncol Biol Phys 2006; 66(3): S366.
42. Alizadeh M, Sylvestre MP, Zilli T et al. Effect of statins and anticoagulants on prostate cancer aggressiveness. Int J Radiat Oncol Biol Phys 2012; 83(4): 1149-1153.
43. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116(14): 3389-3398.
44. Krane LS, Kaul SA, Stricker HJ et al. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183(1): 118-125.
45. Rioja J, Pinochet R, Savage CJ et al. Impact of statin use on pathologic features in men treated with radical prostatectomy. J Urol 2010; 183(4): e51.
46. Ku JH, Jeong CW, Park YH et al. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011; 14(1): 63-68.
47. Mondul AM, Han M, Humphreys EB et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185(4): 1268-1273.
48. Ritch CR, Hruby G, Badani KK et al. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108(8 B): E211-E216.
49. Mass AY, Agalliu I, Laze J et al. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and metaanalysis. J Urol 2012; 188(3): 786-91.
50. Moyad MA, Merrick GS, Butler WM et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26(4): 298-303.
51. Soto DE, Daignault S, Sandler HM et al. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73(1): 158-162.
52. Gutt R, Tonlaar N, Kunnavakkam R et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28(16): 2653-2659.
53. Oh DS, Song H, Freedland S et al. Statin use and prostate cancer recurrence in men treated with brachytherapy. Int J Radiat Oncol Biol Phys 2011; 81(2): S12-S13.
54. Zaorsky NG, Buyyounouski MK, Li T et al. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 2012; 84(1): e13-7.
55. Salih T, Aziz K, Thiyagarajan S et al. Radiosensitization of MYC-overexpressing prostate cancer cells by statins. J Clin Oncol 2011; 29(suppl 7): abstr 260.
56. He Z, Mangala LS, Theriot CA et al. Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells. J Radiat Res 2012; 53(2): 225-233.
57. Nguyen PL, Je Y, Schutz FA et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306(21): 2359-2366.
58. Caporaso NE. Statins and cancer-related mortality-let's work together. N Engl J Med 2012; 367(19): 1848-1850.
59. D'Amico AV. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. J Clin Oncol 2010; 28(16): 2651-2652.
60. Hamilton RJ, Goldberg KC, Platz EA et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100(21): 1511-1518.
61. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med 2012; 366(19): 1752-1755.